Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IASIS phase 2 trial of inhaled amikacin + fosfomycin in mechanically ventilated patients with gram-negative bacterial pneumonia
2013-002855-13Phase 2Completed
- Sponsor
- Cardeas Pharma Corp.
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amikacin and fosfomycin in Gram-negative pneumonia (2 arms), sponsored by Cardeas Pharma Corp. Primary endpoint: Change from baseline in Clinical Pulmonary Infection Score during the planned 10-day treatment period. Started Nov 2013; status: completed.
02
Drugs
amikacinfosfomycin
03
Conditions
Gram-negative pneumonia
Beyond the preview
Go deeper on 2013-002855-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002855-13.